Glyphic Biotechnologies, Inc.
New York, NY Doing business as Glyphic Biotechnologies
- UEI
- F57WT7JZDH19
- CAGE
- 94M19
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 169 Madison Ave #2216, New York, NY 10016, USA
- Website
- glyphic.bio
- Founded
- 2021
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Medical r and d purchase order for a DHA sttr phase i, proposal no. H23C-001-0042, titled, "development of anti-glycan… | Defense Health Agency | $249,993 | |
| Single-molecule protein sequencing: resolving individual amino acids via commercially accessible nanopores - project… | National Institute of General Medical Sciences | $1,599,463 | |
| Single-molecule protein sequencing by barcoding of n-terminal amino acids - summary proteins are responsible for much of… | National Institute of General Medical Sciences | $717,962 | |
| Single-molecule sequencing of post-translational protein modifications - summary proteins are responsible for much of… | National Institute of General Medical Sciences | $817,878 | |
| Single-molecule protein sequencing by detection and identification of n-terminal amino acids - summary - subtle… | National Human Genome Research Institute | $390,584 |
About Glyphic Biotechnologies, Inc.
Glyphic Biotechnologies, Inc., doing business as Glyphic Biotechnologies, is a biotechnology startup focused on developing next-generation protein sequencing technologies. The company specializes in innovative approaches to single-molecule protein sequencing, aiming to revolutionize proteomic analysis by making large-scale protein sequencing feasible, inexpensive, and routine. Glyphic Biotechnologies provides research and development services to the federal government through both contract and grant awards, primarily in the areas of biomedical research, protein analysis, and novel sequencing technologies. The company is registered as a minority-owned, self-certified small disadvantaged business, and manufacturer of goods.
In terms of federal contracts, Glyphic Biotechnologies recently secured a $249,993.28 Small Business Innovation Research (SBIR) Phase I firm-fixed-price purchase order from the U.S. Defense Health Agency (DHA). This contract, awarded on April 8, 2024, focuses on the development of anti-glycan antibodies against multi-drug resistant ESKAPE wound pathogens. The project, set to be completed by November 7, 2024, demonstrates the company's capability to contribute to medical research and development in support of defense-related health initiatives. This contract was awarded under a total small business set-aside, highlighting Glyphic Biotechnologies' status as a small business entity in the federal contracting landscape.
Glyphic Biotechnologies has been particularly active in securing federal grant awards to advance its proprietary protein analysis platform. The company has received multiple grants from the National Institutes of Health, specifically from the National Institute of General Medical Sciences (NIGMS) and the National Human Genome Research Institute (NHGRI). These grants, totaling over $1.9 million, support various aspects of the company's innovative protein sequencing technology. Projects include developing a novel "next-generation" protein sequencing strategy using DNA barcodes, creating reagents for detecting post-translational modifications on individual protein molecules, and developing antibodies for digitally identifying N-terminal amino acids of proteins. These grants aim to enable high-throughput, single-molecule protein sequencing that could analyze complex protein mixtures without prior knowledge, with potential applications in disease diagnosis, biomarker discovery, and advancing protein function research. The funding from these grants is crucial in advancing Glyphic Biotechnologies' goal of making large-scale protein sequencing a routine and cost-effective process in proteomic research and clinical diagnostics.
Quick answers
What is Glyphic Biotechnologies, Inc.'s UEI?
Glyphic Biotechnologies, Inc.'s Unique Entity ID (UEI) in SAM.gov is F57WT7JZDH19.
What is Glyphic Biotechnologies, Inc.'s CAGE code?
Glyphic Biotechnologies, Inc.'s CAGE code is 94M19.
What is Glyphic Biotechnologies, Inc.'s primary NAICS code?
Glyphic Biotechnologies, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Glyphic Biotechnologies, Inc. located?
Glyphic Biotechnologies, Inc.'s physical address in SAM.gov is 169 Madison Ave #2216, New York, NY 10016, USA.
Is Glyphic Biotechnologies, Inc. registered in SAM.gov?
Yes. Glyphic Biotechnologies, Inc.'s SAM.gov registration is active through February 12, 2027.
What is Glyphic Biotechnologies, Inc.'s most recent federal award?
Glyphic Biotechnologies, Inc.'s most recent federal contract award is Medical r and d purchase order for a DHA sttr phase i, proposal no. H23C-001-0042, titled, "development of anti-glycan… (HT942524P0042), from Defense Health Agency, on April 8, 2024.
On GovTribe
See Glyphic Biotechnologies, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors